Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292864 | 0.82 | — | — | |
| Trichlorethanol SCHEMBL29488695 | 0.82 | KDM4E (0.33) | KDM4EMAPK1HIF1APAOXTSHR | |
| Bromide SCHEMBL5490789 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL6045193 | 0.80 | — | — | |
| Water SCHEMBL1551519 | 0.78 | MAOA (0.33) | METAP1KDM4EMAPK1HIF1APAOX | |
| SCHEMBL20880632 | 0.74 | F2 (0.38) | LMNAF2KDM4EMAPK1HIF1A | |
| Chloral Hydrate SCHEMBL5474333 | 0.71 | LMNA (0.50) | LMNAKDM4ECYP2C19 | |
| SCHEMBL11338422 | 0.68 | CYP2C19 (0.42) | KDM4EMAPK1HIF1APAOXCYP2C19 | |
| Chloral Hydrate SCHEMBL28464822 | 0.67 | LMNA (0.60) | LMNACYP2C19TSHR | |
| SCHEMBL7769403 | 0.67 | LMNA (0.34) | LMNATSHRMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095104-A1 | USE OF VASOCONSTRICTORS | ZACHAR ORON (IL) | 2012-04-19 | — | — | US | claimed |
| EP-2376073-A2 | DERMAL APPLICATION OF VASOCONSTRICTORS | Zachar, Oron (IL) | 2011-10-19 | — | — | EP | claimed |
| US-20110144209-A1 | USE OF VASOCONSTRICTORS | ZACHAR ORON | 2011-06-16 | — | — | US | claimed |
| EP-2313037-A1 | DERMAL APPLICATION OF VASOCONSTRICTORS | Zachar, Oron (IL) | 2011-04-27 | — | — | EP | claimed |
| WO-2010063030-A2 | DERMAL APPLICATION OF VASOCONSTRICTORS | FEIGELSON, DANIEL (IL) | 2010-06-03 | — | — | WO | claimed |
| WO-2010001391-A1 | DERMAL APPLICATION OF VASOCONSTRICTORS | ZACHAR ORON (IL) | 2010-01-07 | — | — | WO | claimed |
| WO-2024197124-A9 | ARGININE VASOPRESSIN RECEPTOR (AVPR) ANTAGONISTS AND METHODS OF USING THEREOF | UNIVERSITY OF MIAMI (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024197124-A2 | ARGININE VASOPRESSIN RECEPTOR (AVPR) ANTAGONISTS AND METHODS OF USING THEREOF | UNIVERSITY OF MIAMI (US) | 2024-09-26 | — | — | WO | disclosed |
| WO-2022160065-A1 | FORMULATIONS INCLUDING DIHYDROHONOKIOL | BETTERLIFE PHARMA INC. (CA) | 2022-08-04 | — | — | WO | disclosed |
| EP-3724192-B1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2022-08-03 | — | — | EP | disclosed |
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | RICHTER GEDEON NYRT. (HU) | 2022-04-12 | — | — | US | disclosed |
| US-20200368169-A1 | ABUSE-DETERRENT COMPOSITIONS | PATHEON SOFTGELS INC (US) | 2020-11-26 | — | — | US | disclosed |
| EP-3724192-A1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | Richter Gedeon Nyrt. (HU) | 2020-10-21 | — | — | EP | disclosed |
| WO-2010088911-A1 | PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE | EGALET A/S (DK) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010089132-A1 | IMMEDIATE RELEASE COMPOSITION RESISTANT TO ABUSE BY INTAKE OF ALCOHOL | EGALET A/S (DK) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010083843-A1 | CONTROLLED RELEASE FORMULATIONS WITH CONTINUOUS EFFICACY | EGALET A/S (DK) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010063030-A2 | DERMAL APPLICATION OF VASOCONSTRICTORS | FEIGELSON, DANIEL (IL) | 2010-06-03 | — | — | WO | disclosed |
| EP-2155167-A2 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | Egalet A/S (DK) | 2010-02-24 | — | — | EP | disclosed |
| WO-2010001391-A1 | DERMAL APPLICATION OF VASOCONSTRICTORS | ZACHAR ORON (IL) | 2010-01-07 | — | — | WO | disclosed |
| WO-2008148798-A2 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | EGALET A/S (DK) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | AVPR1B, AVPR1A, AVPR2 | LMNA 1867/4885F2 808/4885METAP1 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.